Active Ingredient History

  • Now
Pardoprunox (INN) is an antiparkinsonian drug developed by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued. It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well.   Wikipedia

  • SMILES: CN1CCN(CC1)c2cccc3NC(=O)Oc23
  • Mol. Mass: 233.27
  • ALogP: 0.87
  • ChEMBL Molecule:
More Chemistry
2(3h)-benzoxazolone, 7-(4-methyl-1-piperazinyl)-monohydrochloride | du-126891 | pardoprunox | slv308 | slv-308 | sme-308


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue